Pompe Disease Infantile-Onset Clinical Trial
Official title:
Expanded Use Of Recombinant Human Acid Alpha-Glucosidase/N-butyl-deoxynojirimycin (ATB200/AT2221) For Patients With Infantile-Onset Pompe Disease
This is an expanded access program (EAP) for eligible participants designed to provide access to ATB200/AT2221.
This program is being offered on a patient by patient basis. ;
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Recruiting |
NCT05619900 -
Registry of Patients Diagnosed With Lysosomal Storage Diseases
|
||
| Recruiting |
NCT05083806 -
MSOT in Pompe Disease
|
N/A | |
| Recruiting |
NCT04755751 -
Exercise Capacity in Response to Enzyme Replacement Therapy in Pediatric Pompe Disease.
|
||
| Recruiting |
NCT05793307 -
Evaluation of the Safety and Efficacy of Infantile-onset Pompe Disease Gene Therapy Drug
|
Phase 1/Phase 2 | |
| Recruiting |
NCT04532047 -
In Utero Enzyme Replacement Therapy for Lysosomal Storage Diseases
|
Phase 1 | |
| Completed |
NCT00763932 -
Extension Study of Long-term Safety and Efficacy of Myozyme in Patients With Pompe Disease Who Were Previously Enrolled in Genzyme Sponsored Enzyme Replacement Therapy (ERT) Studies
|
Phase 2 |